

## Daily evidence digest

2 May 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Household secondary SARS-CoV-2 attack rates, glycaemic control and breakthrough infections, smart lockdowns to control COVID-19

#### Peer reviewed journals featured:

- A systematic review on household secondary SARS-CoV-2 attack rates by variant and vaccination status [here](#)
- A narrative review on the Omicron variant [here](#)
- Observational studies on:
  - Public health impact of COVID-19 vaccines in the US [here](#) and associated editorial [here](#)
  - Glycaemic control and SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes [here](#)
  - Increased emergency cardiovascular events among under-40 population in Israel [here](#)
- Modelling studies on:
  - Smart lockdowns to control COVID-19 [here](#)
  - Risk factors for severe COVID-19 by age [here](#)
  - Trade-offs between health, social and economic outcomes in the management of the pandemic [here](#)
- Commentary on:
  - Disentangling the relative importance of T cell responses in COVID-19 [here](#)

#### Pre-peer review articles featured:

- Mobile primary healthcare for post-COVID patients in rural areas [here](#)

#### Guidance and reports

- The Australian Technical Advisory Group Immunisation (ATAGI) released:
  - Updated advice extending recommended intervals: between primary vaccine doses to 8 weeks; and between infection and subsequent vaccine dose to 3 months [here](#)
  - Guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines [here](#)

#### News and blogs

- NEJM audio interview on communicating COVID-19 science [here](#)
- Drug companies urged to share vaccine technology to boost equity and access [here](#)